Connect with us

Hi, what are you looking for?

World News

Germany’s BioNTech says to set up mRNA vaccine facility in Singapore

BIONTECH SE, the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc PFE.N, acquired a manufacturing facility in Singapore, its first in Asia, the company said on Monday.

The facility, bought from a Novartis unit, will be its first messenger ribonucleic acid, or mRNA, facility in Singapore and support its vaccines production for the Asia Pacific region, BioNTech said in a statement, without disclosing financial details.

MRNA vaccines, which scientists say trick the body into protecting itself against an illness by copying viral proteins, are seen as a safe, speedy alternative to traditional vaccines — especially during a pandemic — since they involve no exposure to the illness.

BioNTech said the facility, which will also double as its regional headquarters, will initially be used to make a range of mRNA-based product candidates as well as authorized vaccines and therapeutics, which may include its COVID-19 vaccine.

The aim is to eventually expand production to other drug classes such as cell therapies, said BioNTech, which also plans to set up research and manufacturing centres in Australia.

The Singapore facility is expected to be fully operational by 2023 and create more than 100 jobs by 2024. — Reuters

    You May Also Like

    Business

    The head of the International Monetary Fund has warned of increased risks to the stability of the financial system after weeks of banking sector...

    Business

    1.22 billion people use Instagram every month. That’s a huge number of Instagrammers trying to hit it big on the platform all at the...

    Business

    Since the rise of online casinos, cybersecurity has become a major concern for both casino operators and players alike. The transactions that go around...

    Business

    The Home Office has made next to no progress in tackling criminal fraud during the past five years, despite it having become Britain’s most...

    Disclaimer: rightdecisionnow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023 rightdecisionnow.com | All Rights Reserved